Cardiac Damage and Clinical Outcomes in Symptomatic Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement
In brief
Severe aortic stenosis patients with right-heart damage faced 20% one-year mortality after TAVR
In a post hoc analysis of 596 patients who underwent transcatheter aortic valve replacement, one-year mortality rose from 0% with no cardiac damage to 20.4% with the most advanced stage, involving right ventricular damage. The staging system separated patients by risk, but this analysis does not show that changing treatment based on stage improves outcomes.
- Journal
- JACC. Cardiovascular interventions (Q1)
- Published
- 9 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Akihiro Tobe, Michele Gallazzi, Niels van Royen, Ignacio J Amat-Santos, Martin Hudec, Matjaz Bunc, et al.
- PMID
- 43003595
- DOI
- 10.1016/j.jcin.2026.07.030
Why clinicians should know about it
- Picked for Cardiology and Cardiovascular Medicine (top studies of the week, 22 November 2026): Echo-based cardiac damage staging predicts mortality after TAVR
Abstract
BACKGROUND: The extent of cardiac damage in patients with aortic stenosis (AS) is associated with worse clinical outcomes. OBJECTIVES: This study sought to investigate the clinical impact of cardiac damage using the updated criteria incorporating the echocardiographic probability of pulmonary hypertension. METHODS: This post hoc subanalysis of LANDMARK trial, which randomized 768 patients with severe AS to the Myval transcatheter heart valve (THV) series or to contemporary THVs (Sapien and Evolut series), used updated cardiac damage classification: stage 0, no cardiac damage; stage 1, left ventricular damage; stage 2, left atrial or mitral valve damage; stage 3, pulmonary artery or tricuspid valve damage; and stage 4, right ventricular damage. The impact of cumulative cardiac damage, defined as meeting all criteria for stages 1 to 4, was also assessed. The primary endpoint was 1-year all-cause mortality. RESULTS: Cardiac damage stages were assessed in 596 patients (stage 0, n = 36; stage 1, n = 88; stage 2, n = 284; stage 3, n = 84; stage 4, n = 104), with a mean age of 80.2 (5.7) years and a mean Society of Thoracic Surgeons score of 3.3% (2.4%). One-year mortality was 0%, 1.1%, 4.7%, 7.2%, and 20.4% in stages 0, 1, 2, 3, and 4, respectively (log-rank P < 0.001). The area under the curve for predicting 1-year mortality was 0.739. Patients with cumulative cardiac damage had the highest mortality (23.6%). In the multivariable analysis, stage 4 was independently associated with higher 1-year mortality. CONCLUSIONS: The updated cardiac damage staging stratified 1-year mortality after transcatheter aortic valve replacement, highlighting the importance of comprehensive echocardiographic assessment in severe AS. (LANDMARK Trial: a Randomised Controlled Trial of Myval THV [LANDMARK]; NCT04275726).
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.